Global News

The Pulse on Technology

Monday, June 23, 2014 07:29 AM

Managing clinical trials is an enormously complex endeavor and requires sufficient business acumen and rigorous decision making.

More... »

WIRB Copernicus Group

Johnson & Johnson Innovation announces 12 new life science alliances

Friday, June 20, 2014 02:10 PM

Johnson & Johnson Innovation has announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across pharmaceuticals, medical device and diagnostics and consumer healthcare.

More... »

CRF Health eCOA webinar series

Shire confirms rejection of AbbVie proposal

Friday, June 20, 2014 01:47 PM

Shire has confirmed it has rejected the May 30 unsolicited and highly conditional proposal from AbbVie regarding a possible cash and share offer for Shire. 

More... »

Celsion completes acquisition of Egen

Friday, June 20, 2014 01:04 PM

Celsion, an oncology drug development company, has completed its acquisition of substantially all of the assets of Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition includes Egen’s phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

More... »

SillaJen Biotherapeutics completes name change

Friday, June 20, 2014 01:01 PM

SillaJen, a privately held biotherapeutics company focused on development of targeted oncolytic immunotherapy products for cancer, has completed its name change to SillaJen Biotherapeutics following its acquisition of Jennerex Biotherapeutics.

More... »

BIND Therapeutics, Roche collaborate on discovery of novel nanomedicines

Friday, June 20, 2014 12:07 PM

BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND's Accurin technology with Roche's proprietary therapeutic payloads and targeting ligands.

More... »

Kibow Biotech is a "Buzz of BIO" award winner

Thursday, June 19, 2014 02:52 PM

Kibow Biotech is winner of a 2014 BIO International Convention "Buzz of BIO Award," and is the first biotechnology company specializing exclusively in dietary supplement products to receive the honor during BIO's 29-year history. BIO is the world's largest trade association, representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and more than 30 other nations. BIO member companies are involved in the R&D of innovative healthcare, agricultural, industrial and environmental biotechnology products.

More... »

Bellerophon completes enrollment for phase II trial of INOpulse for PAH

Thursday, June 19, 2014 02:46 PM

Bellerophon Therapeutics, a clinical stage biotherapeutics company has completed enrollment of its 80-patient phase II clinical trial of INOpulse for the treatment of pulmonary arterial hypertension (PAH). PAH is a life-threatening, progressive disorder characterized by abnormal constriction of the arteries of the lung, leading to increased blood pressure in the lungs and abnormal strain on the heart's right ventricle, eventually leading to heart failure.

More... »

Sorbent Therapeutics appoints two new board members

Thursday, June 19, 2014 02:27 PM

Sorbent Therapeutics, a biopharmaceutical company developing therapies for cardiovascular and renal diseases, has appointed Jay Shepard and William D. Waddill to the company's board of directors.

More... »

Debiopharm Group initiates phase I study of Debio 1450 for staphylococcal infections

Thursday, June 19, 2014 02:16 PM

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, has launched a phase I dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs